Anticancer Bioscience announces CNY63m financing to advance its synthetic lethal platform and pre-clinical oncology pipeline.
FREMONT, CA: Anticancer Bioscience (ACB), pioneers in synthetic lethal methods to precision oncology, closes successful round additional financing round, raising CNY63m. It has already gained positive animal data in its molecule program targeting MYC over expression. The financing, by a syndicate of undisclosed, experienced Chinese angel investors, adds to the seed financing of CNT68.75m and is being leveraged to further expand ACB’s proprietary screening libraries discovery platforms, progressing two of its programs towards IND, allowing studies this year.
ACB is an international private firm commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research.
The firm uses its unique screening libraries and discovery platforms in cancer biology to uncover new mechanisms to comprise cancer cell death without harming healthy cells. Synthetic lethality is possible when the genetic changes that allow carcinogenesis also make the cancer cell overly dependent on specific pathways and proteins. Attacking these dependencies with drugs can yield anti-cancer effects while leaving normal cells healthy. Synthetic lethality allows targeting of drivers of carcinogenesis that are not presently amenable to drug development.
ACB has invested in small molecule and natural product libraries that comprise new scaffolds of drug-like molecules and natural medicinal botanicals. ACB’s small molecule libraries are based on new scaffolds upon which further diversity can be assembled. These utility new scaffold-drug fragment libraries are being widened and evolved through iterative optimization processes for several phenotypic screening projects.
In the firm’s lead MYC inhibition program, a novel chemical series with low nM activity has been found in model cell lines. The synthetic lethal phenotype comprises the induction of cell cycle arrest early in mitosis followed by accumulation of polyploid cells. ACB is exploring a second MYC inhibitory compound series.
ACB’s objective is to create first-in-class oncology drugs for a broad range of indications, focusing on therapies disabling untargeted mitotic regulators. Overexpression of MYC engenders vulnerability in mitosis and several other cellular operations. It is the commonly deregulated oncoprotein, targeting synthetic lethality, an attractive strategy for cancer therapy.